Truist Assigns Buy Rating to Genmab (GMAB)

On May 27, sum of Genmab A/S (NASDAQ:GMAB) was resumed by Truist expert Gregory Renza. The expert reduced the terms people from $48 to $40 and assigned a Buy standing to the stock. He shared an optimistic presumption astir the institution pursuing its displacement towards a commercially focused concern platform. This is backed by 3 cardinal assets comprising astir 7 important readouts during 2026.

Pressmaster/Shutterstock.com

According to Renza, Rina-S and petosemtamab person the imaginable to beryllium best- oregon first-in-class successful ovarian crab and HNSCC, respectively, portion Epkinly’s DLBCL-2/-4 results are important for franchise expansion.

Back connected April 30, H.C. Wainwright reduced the people terms connected Genmab A/S (NASDAQ:GMAB) from $40 to $38, starring to an adjusted upside imaginable successful excess of 54%. The steadfast upheld its Buy standing connected the shares.

Based connected Pfizer’s MagnetisMM-5 proceedings outcomes, the steadfast anticipates a beardown probability that, among physicians, Elrexfio volition beryllium favored implicit dexamethasone successful treating relapsed oregon refractory aggregate myeloma patients who person undergone astatine slightest 1 anterior enactment of therapy.

Genmab A/S (NASDAQ:GMAB) is simply a biotechnology institution based successful Denmark that is engaged successful processing antibodies and related products to cure crab and different diseases. The institution markets assorted cures for adults, including EPKINLY, TEPKINLY, and Tivdak.

While we admit the imaginable of GMAB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.